Key Laboratory of Drug Quality Control and Pharmacovigilance (Ministry of Education), State Key Laboratory of Natural Medicine, China Pharmaceutical University, Nanjing 210009, P. R. China.
State Key Laboratory for Quality Research in Chinese Medicines, Macau University of Science and Technology, Taipa, Macau, China.
Phytomedicine. 2020 Jul;72:153236. doi: 10.1016/j.phymed.2020.153236. Epub 2020 May 18.
Intestinal obstruction (IO) is a kind of acute abdomen with high morbidity and mortality. Patients suffer from poor quality of life and tremendous financial pressure. Da-Cheng-Qi decoction (DCQD), a classical purgation prescription, has clinically been proven to be an effective treatment for IO.
Network pharmacology integrated with bioactive equivalence assessment was used to discover the quality marker (Q-marker) of DCQD against IO.
As there is hardly any targets recorded in database, thus the collection of IO targets was conducted by searching those of alternative diseases which have similar pathological symptoms with IO. In order to improve the reliability of the obtained targets, IO metabolomics data was introduced. Active compounds combination (ACC) was focused as potential Q-markers via component-target network analysis and function query from the identified components corresponding to the common targets. Bioequivalence between ACC and DCQD was assessed from the aspects of intestine motility (somatostatin secretion), inflammation (IL-6 secretion) and injury (wound healing assay) in vitro and was further validated in ileus rat model. PPI network analysis of core targets followed by gene pedigree classification and experimental validation confirmed the potential intervention pathway.
A combination of 11 ingredients, including emodin, physcion, aloe-emodin, rhein, chrysophanol, gallic acid, magnolol, honokiol, naringenin, tangeretin, and nobiletin was finally confirmed bioequivalence with DQCD to some extent and could serve as Q-markers for DCQD to attenuate IO. PI3K/AKT was verified as a possible affected pathway that DCQD exerted the effectiveness against IO.
For the disease with few recorded targets, searching those of alternative diseases which have similar pathological symptoms could be a feasible and effective approach. The proposed network pharmacology integrated bioactive equivalence evaluation paradigm is efficient to discover Q-marker of herbal formulae.
肠梗阻(IO)是一种发病率和死亡率都很高的急性腹痛。患者生活质量差,经济压力大。大承气汤(DCQD)是一种经典的泻下方剂,已临床证明对 IO 有效。
采用网络药理学结合生物等效性评价,发现 DCQD 治疗 IO 的质量标志物(Q-marker)。
由于数据库中几乎没有记录任何靶点,因此通过搜索与 IO 具有相似病理症状的替代疾病的靶点来收集 IO 靶点。为了提高获得靶点的可靠性,引入了 IO 代谢组学数据。通过对鉴定的成分对应的共同靶点进行成分-靶点网络分析和功能查询,将活性化合物组合(ACC)作为潜在的 Q-标志物。从肠动力(生长抑素分泌)、炎症(IL-6 分泌)和损伤(伤口愈合试验)等方面评估 ACC 与 DCQD 的生物等效性,并在肠梗大鼠模型中进行验证。通过核心靶点的 PPI 网络分析,结合基因谱系分类和实验验证,证实了潜在的干预途径。
最终确定了由 11 种成分组成的组合,包括大黄素、大黄酸、芦荟大黄素、大黄素、大黄酚、没食子酸、厚朴酚、和厚朴酚、柚皮苷、橙皮苷和川陈皮素,与 DCQD 具有一定的生物等效性,可以作为 DCQD 减轻 IO 的 Q-标志物。PI3K/AKT 被验证为 DCQD 对 IO 发挥疗效的可能影响途径。
对于靶点记录较少的疾病,搜索具有相似病理症状的替代疾病的靶点是一种可行且有效的方法。所提出的网络药理学结合生物等效性评价的方法是有效的,可用于发现草药配方的 Q-标志物。